—
C+
C+ The full Closelook — membership. Open the C+ overview

Novocure Ltd (NVCR) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Novocure Ltd

NVCR in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Novocure develops, manufactures and sells tumour treating fields devices, wearable systems that deliver low-intensity electric fields to disrupt the division of cancer cells in solid tumours. Its marketed products, Optune Gio, Optune Lua and Optune Pax, address specific cancers and are sold in the United States, Germany, France, Japan, Greater China and other markets. The company also runs trials testing the same technology in brain metastases, gastric, glioblastoma, liver, lung, pancreatic and ovarian cancers. It is headquartered in Baar, Switzerland.
Where it sits in the stack
Novocure carries no seat in Rubin, our AI build-out index, so it sits outside that stack entirely. Within our wider universe it belongs to the Healthcare sector, medical devices sleeve, alongside other therapeutic-device makers rather than any layer of the compute build-out.
Who it is priced against
Closelook has not set a peer group for Novocure. The market sometimes places it alongside other therapeutic medical-device makers such as Medtronic, though the comparison is loose given how specific its tumour treating fields technology is.
Why Closelook tracks it
Novocure is a Russell 1000 constituent; Closelook has not built a score for it, and the diary has not yet quoted the name in any edition.
What the diary watches
The diary watches whether trial results in cancers beyond its current approvals, such as lung, liver or pancreatic cancer, would widen the addressable use of its devices.

Novocure Ltd (NVCR) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for NVCR, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Medical Devices · United States · 8 names with week and year-to-date

Peer group

Medical Devices · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against NVCR on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Novocure Ltd (NVCR)?

Novocure Ltd trades as NVCR on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is NVCR in a Closelook index?

Not currently — Novocure Ltd is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does NVCR trade against its moving averages?

Pullback inside an uptrend stack: Trades -0.2% vs the 50-day and +14.8% vs the 200-day average, 22.2% below the 52-week high and +70% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Novocure Ltd do?

Novocure develops, manufactures and sells tumour treating fields devices, wearable systems that deliver low-intensity electric fields to disrupt the division of cancer cells in solid tumours. Its marketed products, Optune Gio, Optune Lua and Optune Pax, address specific cancers and are sold in the United States, Germany, France, Japan, Greater China and other markets. The company also runs trials testing the same technology in brain metastases, gastric, glioblastoma, liver, lung, pancreatic and ovarian cancers. Closelook has not set a peer group for Novocure. The market sometimes places it alongside other therapeutic medical-device makers such as Medtronic, though the comparison is loose given how specific its tumour treating fields technology is.

Where does Novocure Ltd sit in the AI build-out?

Novocure carries no seat in Rubin, our AI build-out index, so it sits outside that stack entirely. Within our wider universe it belongs to the Healthcare sector, medical devices sleeve, alongside other therapeutic-device makers rather than any layer of the compute build-out. Novocure is a Russell 1000 constituent; Closelook has not built a score for it, and the diary has not yet quoted the name in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for NVCR, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.